Sales force largely intact following Astellas merger

Share this article:

The merger of two Japanese pharmaceutical giants into Astellas hit Yamanouchi Pharma America headquarters staff but left its sales force largely unscathed.
Yamanouchi was folded into Fujisawa earlier this month to form Astellas, pairing the former's urology franchise and primary care reach with the latter's diverse specialty
portfolio.
The company's field-based sales force of around 140, which last year launched Vesicare for overactive bladder with GlaxoSmithKline, was spared deep cuts. Astellas officials
did not disclose the number of Yamanouchi Pharma America staff that had left or been laid off, but said around 200 Yamanouchi employees joined Astellas, including sales reps.
The company's headquarters marketing staff alone had numbered
around 200.
The combined company boasts 1,900 U.S. employees and drugs including Yamanouchi BPH drug Flomax, a co-promote with Boehringer Ingelheim, Vesicare and Fujisawa's flagship eczema treatment, Protopic. Astellas also has products in transplants, cardiovascular and infectious diseases.
The firm's pipeline includes a treatment for acne vulgaris, and Mycamine, an anti-infective for the treatment of candida fungal infections, was approved in March and will launch in May.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.